NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Neogen Chemicals has approved its FY26 audited results and recommended a final dividend of Re. 1 per share. The company announced a significant revision in the project timelines and costs for its subsidiary, Neogen Ionics Limited (NIL), with total costs now projected at Rs. 1,795 crore. These projects in Dahej and Pakhajan are now expected to be completed by February and March 2027, respectively, due to a shift to Japanese technology and increased localization. Additionally, the company has recovered Rs. 140 crore of its insurance claim from a 2025 fire incident, with Rs. 188.96 crore still outstanding.
முக்கிய அம்சங்கள்
Recommended a final dividend of Re. 1 per equity share for the financial year 2025-26.Revised total project cost for Neogen Ionics Limited (NIL) to Rs. 1,795 crore (Dahej: Rs. 428 Cr, Pakhajan: Rs. 1,367 Cr).Project timelines for NIL extended to Feb/Mar 2027 due to design optimization and adoption of Japanese technology.Outstanding insurance claim receivable stands at Rs. 188.96 crore as of March 31, 2026.Funding for additional capex to be met through promoter equity infusion and planned JV partner contributions.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the Neogen Ionics project as the timeline has shifted to 2027 with increased costs. The successful recovery of the remaining Rs. 188.96 crore insurance claim remains a critical factor for the company's cash flow.
Neogen Chemicals Subsidiary to Invest ₹100.11 Cr in Step-Down Subsidiary for EV Battery Materials
Neogen Chemicals' wholly-owned subsidiary, Neogen Ionics Limited (NIL), has approved an investment of ₹100.11 crore in its step-down subsidiary, Neogen Morita New Material Limited (NML). The investment will be executed through a rights issue of 71,00,000 equity shares at a price of ₹141 per share. This capital infusion is specifically targeted at the Lithium-Ion Battery material space, focusing on electrolyte salts for both internal consumption and global markets. The move signifies Neogen's aggressive expansion into the electric vehicle supply chain ecosystem.
முக்கிய அம்சங்கள்
Investment of ₹100.11 crore via rights issue in step-down subsidiary Neogen Morita New Material Limited (NML).Subscription of 71,00,000 equity shares at ₹141 per share (including a premium of ₹131).NML's authorized share capital increased from ₹5 crore to ₹9.9 crore to accommodate the issuance.Funds earmarked for acquiring salt business, CAPEX, and OPEX requirements for Lithium-Ion Battery materials.The transaction is expected to be completed within 60 days of receipt of share application money.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Lithium-Ion Battery material project as it represents a high-growth vertical for the company. While the investment is strategic, the long-term impact will depend on the successful execution of CAPEX and market adoption of their electrolyte salts.
Neogen Chemicals Allots 10 Lakh Shares to Promoter Group for Rs 161 Crore
Neogen Chemicals has completed a preferential allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a member of the promoter group. The allotment was executed at a price of Rs. 1,610 per share (including a premium of Rs. 1,600), resulting in a total capital infusion of Rs. 161 crore. This transaction increases the promoter group's holding, with this specific entity now owning 3.65% of the post-allotment paid-up capital. Such a significant investment by promoters at a premium is generally viewed as a strong signal of confidence in the company's future growth.
முக்கிய அம்சங்கள்
Allotment of 10,00,000 equity shares at an issue price of Rs. 1,610 per shareTotal investment amount aggregates to Rs. 161 crore for cash considerationAcquisition constitutes 3.65% of the post-allotment paid-up equity capitalTotal paid-up equity capital increased from Rs. 26.38 crore to Rs. 27.38 croreThe acquirer, Cadamba Solutions Private Limited, belongs to the promoter group
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive indicator of promoter commitment and confidence in the company's valuation. Monitor the company's upcoming quarterly results to see how this additional capital is deployed for expansion.
Neogen Chemicals has completed the allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a promoter group entity, on a preferential basis. The shares were issued at a price of Rs. 1,610 per share, which is a significant 17.02% premium over the regulatory floor price of Rs. 1,375.82. This move has successfully raised Rs. 161 crore for the company, increasing its paid-up equity capital to Rs. 27.38 crore. The infusion of capital by the promoter group at a premium indicates strong internal confidence in the company's future prospects.
முக்கிய அம்சங்கள்
Allotted 10,00,000 equity shares at Rs. 1,610 per share, aggregating to Rs. 161 croreIssue price of Rs. 1,610 is 17.02% higher than the SEBI floor price of Rs. 1,375.82The entire allotment was made to Cadamba Solutions Private Limited, a Promoter Group memberPaid-up equity share capital increased from Rs. 26.38 crore to Rs. 27.38 croreAllotted shares are subject to a lock-in period of 18 months as per SEBI ICDR Regulations
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive signal of promoter commitment and financial backing at a premium valuation. Monitor the company's upcoming quarterly results to see how this capital infusion is deployed for growth initiatives.
Neogen Chemicals Promoter Discloses Pledge of 13.19 Lakh Equity Shares
Dr. Harin Kanani, representing the Haridas Kanani Family Trust, has submitted a mandatory annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The disclosure confirms that the promoter group maintained its shares without encumbrance for most of the year, except for a specific pledge. On March 30, 2026, a pledge was created on 13,19,083 equity shares held by Dr. Harin Kanani. This filing ensures transparency regarding promoter shareholding and any potential liens on their stake.
முக்கிய அம்சங்கள்
Pledge created on 13,19,083 equity shares of Neogen Chemicals LimitedEncumbrance was established by Dr. Harin Kanani on March 30, 2026Declaration filed under Regulation 31(4) of SEBI (SAST) Regulations, 2011No other creation, invocation, or release of encumbrance occurred during FY 2025-26
👀 கவனிக்க வேண்டியவை
Investors should monitor the total percentage of promoter equity now pledged to assess any potential risk of margin calls. While pledging is a common financing tool, a significant increase in encumbered shares can impact market sentiment.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Neogen Chemicals Shareholders Approve Preferential Issue to Promoters with 99.99% Majority
Neogen Chemicals Limited has received overwhelming shareholder approval for the issuance of equity shares on a preferential basis to a member of the promoter group. During the Extraordinary General Meeting (EGM) held on March 29, 2026, the special resolution was passed with 99.9999% of the votes in favor. A total of 2,04,17,139 valid votes were cast, with only 20 votes against the proposal. This capital infusion from the promoters is expected to strengthen the company's financial position and signals strong promoter confidence.
முக்கிய அம்சங்கள்
Special resolution for preferential issuance of equity shares to the Promoter group was approved.The resolution received 2,04,17,119 votes in favor, accounting for 99.9999% of total valid votes.Only 20 votes (0.0001%) were cast against the proposal during the voting process.The EGM was conducted via Video Conferencing with remote e-voting held between March 26 and March 28, 2026.The Scrutinizer's report confirmed the resolution was passed with the requisite majority as a Special Resolution.
👀 கவனிக்க வேண்டியவை
Investors should take this as a positive sign of promoter commitment and financial support for the company's growth plans. Monitor for further disclosures regarding the specific allotment price and the intended use of the raised capital.
Neogen Chemicals EGM Approves Preferential Equity Issue to Promoter Group
Neogen Chemicals Limited held an Extraordinary General Meeting (EGM) on March 29, 2026, to seek shareholder approval for a preferential issue of equity shares to its promoter group. During the meeting, management addressed shareholder queries regarding the utilization of proceeds and the impact of current geopolitical situations on the company. The resolution was proposed as a Special Resolution, indicating a significant corporate action to raise capital from internal stakeholders. Final voting results and the specific quantum of the fundraise are expected to be disclosed within 48 hours.
முக்கிய அம்சங்கள்
Special Resolution proposed for the issuance of equity shares on a preferential basis to the Promoter group.Management clarified the object of the issue and the planned utilization of proceeds during the meeting.The EGM was held on March 29, 2026, and concluded with a facility for electronic voting for all members.The company addressed concerns regarding foreign investor shareholding and current geopolitical impacts.Final scrutinizer's report and voting results to be released within 48 hours of the meeting conclusion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming disclosure for the specific issue price and total amount being raised, as promoter participation typically signals long-term confidence.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue for Battery Materials Expansion
Neogen Chemicals is proceeding with a preferential issue of 10,00,000 equity shares to a promoter group entity, Cadamba Solutions, at a price of Rs 1,610 per share, which is a premium over the floor price. The total fundraise of approximately Rs 161 crore will primarily fund the company's entry into the battery chemicals space through its subsidiary, Neogen Ionics Limited. A significant portion of Rs 100 crore is earmarked for a large-scale greenfield project in Gujarat with a total estimated capex of Rs 1,500 crore. This project targets the Lithium-Ion battery market and is expected to generate peak revenues between Rs 2,500 crore and Rs 2,950 crore.
முக்கிய அம்சங்கள்
Preferential allotment of 10 lakh shares to promoter group at Rs 1,610 per share, totaling Rs 161 crore.Rs 100 crore allocated for investment in Neogen Ionics Limited for battery chemical manufacturing facilities.Total project capex estimated at Rs 1,500 crore with a peak revenue potential of Rs 2,500-2,950 crore.Expansion includes 30,000 MTA Electrolyte capacity and 5,500 MTA Specialty Lithium Salts/Additives capacity.Funds to be utilized within 90 days of allotment for expansion, working capital (Rs 21 cr), and general purposes (Rs 40 cr).
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the high-value battery materials project as it represents a significant strategic pivot. The promoter's capital infusion at a premium to the floor price is a strong signal of confidence in the company's long-term growth prospects.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, totaling Rs 161 crore. The shares are being issued on a preferential basis to Cadamba Solutions Private Limited, a promoter group entity. This issue price represents a significant 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this capital infusion.
முக்கிய அம்சங்கள்
Issuance of 1,000,000 equity shares at Rs 1,610 each, aggregating to Rs 161 croreThe issue price is 17.02% higher than the SEBI-calculated floor price of Rs 1,375.82The entire allotment is directed to Cadamba Solutions Private Limited, part of the promoter groupPost-allotment, the allottee will hold a 3.65% stake in the companyExtraordinary General Meeting (EGM) set for March 29, 2026, with a record date of March 20, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive signal as the promoters are increasing their stake at a significant premium to the floor price. Monitor the company's subsequent announcements regarding the specific utilization of these funds for growth or debt reduction.
Neogen Chemicals Q3 FY26 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Promoter Fundraise
Neogen Chemicals reported a 9% YoY revenue growth to ₹220 crore in Q3 FY26, driven by a 35% surge in the inorganic chemicals segment. While gross margins expanded by 150 bps, PAT remained suppressed at ₹4 crore due to high interest costs and transient expenses related to the Neogen Ionics ramp-up. The company is on track to commission its rebuilt Dahej plant in Q1 FY27 and has secured a ₹150 crore preferential equity infusion from promoters. Additionally, a strategic JV with Japan's Morita Investment is progressing with a $20 million incoming investment for battery material production.
முக்கிய அம்சங்கள்
Q3 FY26 revenue grew 9% YoY to ₹220 crore, with inorganic chemicals growing 35% to ₹33 crore.Net profit stood at ₹4 crore, impacted by ₹1,175 crore consolidated net debt and front-loaded expansion costs.Board approved a ₹150 crore preferential share issue to promoters to provide financial flexibility for growth.Insurance claim of ₹251.12 crore is pending, with ₹60 crore expected immediately and the bulk by March 2026.Battery materials division (Neogen Ionics) contributed ₹12 crore; Pakhajan project on track for FY27 production.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the Dahej and Pakhajan facilities and the receipt of insurance claims to deleverage the balance sheet. The promoter's ₹150 crore infusion is a positive signal of confidence despite current margin pressures from expansion.
Neogen Chemicals has received a third on-account insurance payment of Rs 60 Crore following the fire incident at its Dahej SEZ facility in March 2025, bringing total recoveries to Rs 140 Crore. The company has recognized a consolidated loss of Rs 362.90 Crore but expects to recover Rs 348.82 Crore through insurance, resulting in a net impact of only Rs 14.08 Crore. While the affected MPP3 plant remains suspended, a replacement facility is scheduled for commissioning in Q1 FY27. To mitigate earnings impact, the company has shifted critical production to other sites and is leveraging its Patancheru plant expansion.
முக்கிய அம்சங்கள்
Received Rs 60 Crore as the third on-account insurance payment, totaling Rs 140 Crore to date.Consolidated loss recognized at Rs 362.90 Crore against an expected insurance recovery of Rs 348.82 Crore.Net financial impact on the company estimated at Rs 14.08 Crore on a consolidated basis.Replacement plant construction is underway with a target commissioning date of Q1 FY27.Production of critical specialty products shifted to other sites and Patancheru plant to minimize earnings impact.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline for the replacement plant scheduled for Q1 FY27 and the company's ability to maintain margins while operating from alternative sites. The steady inflow of insurance claims is a positive sign for liquidity and asset recovery.
Neogen Chemicals Q3 FY26 Revenue up 9% to ₹220 Cr; PAT drops 63% on Transitory Costs
Neogen Chemicals reported a 9% YoY growth in consolidated revenue to ₹220 crore for Q3 FY26, supported by steady demand in organic and inorganic chemicals. However, consolidated PAT plummeted 63% to ₹3.7 crore, primarily due to elevated interest costs (₹21.5 crore), higher insurance premiums following a fire incident, and pre-operative expenses for the battery chemicals division. The company is executing a massive ₹1,500 crore CAPEX plan for Neogen Ionics, targeting peak revenues of up to ₹2,950 crore by FY29. To support this growth, the Board has approved a ₹150 crore preferential issue to the Promoter Group.
முக்கிய அம்சங்கள்
Consolidated Revenue increased 9% YoY to ₹220 crore, while Standalone Revenue grew 8% to ₹215.6 crore.Consolidated PAT declined 63% YoY to ₹3.7 crore due to a 60% surge in interest costs and fire-related operational headwinds.Neogen Ionics (Battery Chemicals) reported ₹12 crore in revenue for Q3 FY26, with the Pakhajan Greenfield project on track for H1 FY27.The company has received ₹83.48 crore in insurance claims so far, with a net receivable of ₹251.12 crore still pending.Board approved a ₹150 crore preferential equity issue to promoters to reinforce the company's capital base for expansion.
👀 கவனிக்க வேண்டியவை
Investors should focus on the commissioning timelines of the Pakhajan plant in FY27 and the normalization of interest costs as insurance payouts are received. While current profitability is under pressure, the long-term growth trajectory in the battery chemicals segment and promoter backing remain key positive triggers.
Neogen Chemicals Q3 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Fundraise via Promoters
Neogen Chemicals reported a 9% YoY revenue growth to INR 220 crore in Q3 FY26, driven by volume growth in organic and inorganic chemicals. While consolidated PAT rose 63% to INR 4 crore, profitability was weighed down by finance costs and transitory expenses related to the Dahej plant fire and battery chemical expansions. The company is raising INR 150 crore from promoters to fuel growth and has formed a strategic JV with Japan's Morita Investment for lithium salt production. Progress on the Pakhajan Greenfield project remains on track for commissioning in FY27.
முக்கிய அம்சங்கள்
Consolidated Revenue grew 9% YoY to INR 220 crore; Standalone PAT stood at INR 9 croreBoard approved raising up to INR 150 crore through a preferential issue to the Promoter GroupReceived INR 83.48 crore in insurance claims for the Dahej fire; net receivable remains at INR 251.12 croreFormed an 80:20 JV with Japan’s Morita Investment for global LiPF6 salt productionPakhajan Electrolyte plant nearing mechanical completion with commercial production expected in H1 FY27
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Pakhajan facility and the recovery of insurance claims, which are expected to normalize interest costs. The promoter-led fundraise and Japanese JV signal strong long-term confidence in the battery materials segment.
Neogen Chemicals Q3 Net Profit Drops 39% YoY to ₹8.77 Cr Despite 7.6% Revenue Growth
Neogen Chemicals reported a mixed performance for Q3 FY26, with revenue from operations growing 7.6% YoY to ₹215.60 crore. However, net profit saw a sharp decline of 39.1% YoY to ₹8.77 crore, primarily driven by a 74.8% surge in finance costs which reached ₹22.85 crore. The company is still recovering from the March 2025 fire at its Dahej SEZ plant, having received ₹80 crore in insurance payments to date. While operating margins remained stable at 17%, the increased debt burden and interest expenses are significantly weighing on the bottom-line profitability.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.Net profit declined to ₹8.77 crore compared to ₹14.41 crore in the corresponding quarter of the previous year.Finance costs spiked significantly to ₹22.85 crore from ₹13.07 crore YoY, reflecting higher borrowing costs.The company has received ₹80 crore in on-account insurance payments for the Dahej plant fire loss as of December 2025.Operating margin stood at 17%, while the net profit margin contracted to 4% from 7% YoY.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as rising finance costs and debt levels are eroding the benefits of revenue growth. Monitor the progress of the remaining insurance claims and the company's ability to deleverage its balance sheet in the coming quarters.
Neogen Chemicals Q3 Profit Drops to ₹8.77 Cr; Board Approves Fundraise via Preferential Issue
Neogen Chemicals reported a 39% YoY decline in net profit to ₹8.77 crore for Q3 FY26, despite a 7.5% increase in revenue to ₹215.60 crore. The company's board has granted in-principle approval for a fundraise through a preferential issue of equity shares to bolster its financial position. Operations are still recovering from a significant fire at the Dahej SEZ plant in March 2025, with ₹80 crore in insurance payments received to date against a total claim of ₹334.60 crore. Elevated finance costs of ₹22.85 crore significantly weighed on the quarterly performance.
முக்கிய அம்சங்கள்
Revenue from operations increased 7.5% YoY to ₹215.60 crore in Q3 FY26.Net Profit (PAT) fell to ₹8.77 crore from ₹14.41 crore in the previous year's corresponding quarter.Board approved raising funds through a preferential issue of equity shares.Received ₹80 crore in insurance on-account payments against a total fire-related claim of ₹334.60 crore.Finance costs surged to ₹22.85 crore, up from ₹13.07 crore in Q3 FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the pricing and size of the upcoming preferential issue as it will result in equity dilution. While the revenue growth is positive, the recovery of the remaining insurance claim and management's ability to control rising finance costs are critical for margin improvement.
Neogen Chemicals Q3 FY26 Revenue up 7.6% YoY to ₹215.6 Cr; PAT Declines 39% on Higher Finance Costs
Neogen Chemicals reported a modest revenue growth of 7.6% YoY to ₹215.60 crore for the quarter ended December 31, 2025. However, Net Profit (PAT) saw a significant decline of 39.1% YoY, dropping to ₹8.77 crore from ₹14.41 crore in the previous year's corresponding quarter. This bottom-line pressure is primarily attributed to a 74.8% surge in finance costs, which rose to ₹22.85 crore. The company is still managing the aftermath of a major fire at its Dahej plant from March 2025, having received ₹80 crore in insurance payments during the current fiscal year so far.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.Net Profit (PAT) fell to ₹8.77 crore in Q3 FY26 compared to ₹14.41 crore in Q3 FY25.Finance costs spiked significantly to ₹22.85 crore in Q3 FY26 from ₹13.07 crore in Q3 FY25.Received ₹80 crore as on-account insurance payments for the Dahej plant fire incident during the nine months ended Dec 2025.Inventory turnover days increased to 197 days, up from 162 days in the preceding quarter (Sep 2025).
👀 கவனிக்க வேண்டியவை
Investors should monitor the rising finance costs and debt levels, as the debt-to-equity ratio stands at 0.89. While revenue growth is steady, the sharp decline in profitability and increased inventory days suggest operational and financial headwinds that require caution.
Neogen Chemicals Promoter Transfers 21.9% Stake to Family Trusts via Gift
Haridas Thakarshi Kanani, Promoter and Chairman Emeritus of Neogen Chemicals, has transferred 57,78,500 equity shares, representing 21.90% of the company's paid-up capital. The transfer was executed as a gift through off-market transactions to the Haridas Kanani Family Trust and H T Kanani Family Trust. This internal restructuring follows a SEBI exemption order dated December 30, 2025, for estate planning purposes. While the individual promoter's direct holding decreased to 1.42%, the overall promoter group's control remains unchanged.
முக்கிய அம்சங்கள்
Promoter Haridas Thakarshi Kanani gifted 57,78,500 shares (21.90% stake) to family trustsHaridas Kanani Family Trust acquired 52,76,500 shares, representing approximately 20% stakeH T Kanani Family Trust acquired 5,02,000 shares, representing approximately 1.9% stakeTransaction conducted as an off-market inter-se transfer following a SEBI Exemption OrderIndividual promoter's direct stake reduced from 23.33% to 1.42% post-transfer
👀 கவனிக்க வேண்டியவை
This is a routine internal restructuring for estate planning and does not involve a market sale or change in management control. Investors should treat this as a neutral administrative update with no impact on company fundamentals.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
